Registry & Real-World Data Digest — Issue 03

IJsbrand den Rooijen, Giacomo Capone, Jacobus van Wyk, et al.

Summary: This Lancet Digital Health Viewpoint, emerging from a January 2024 workshop under the EU's Accelerating Clinical Trials (ACT EU) initiative, surveys the largely untapped potential of European clinical trial registry data—nearly 55,000 trials as of mid-2025. The authors identify three thematic use cases: optimizing trial design using historical registry data, improving patient-centricity, and strengthening evidence evaluation for regulatory and policy decisions. Four core enablers are identified: data standardization, data quality, interoperability, and transparency. A concrete early output is the ACT EU trial map, a patient-facing trial discovery platform developed by the European Medicines Agency.

Why it matters: Clinical trial registries represent a substantial and underutilized secondary data resource. If registry data were systematically standardized and made interoperable with real-world data sources, they could meaningfully improve trial planning, reduce duplication, identify evidence gaps, and accelerate regulatory decision-making. For rare diseases in particular—where trial populations are small, evidence is scarce, and individual studies are rarely definitive—aggregating and cross-linking registry data could have outsized value. The workshop's multi-stakeholder framing also signals that the EU regulatory ecosystem is moving, even if slowly, toward a more structured data infrastructure.

Expert perspective: This is a thoughtful consensus document rather than an empirical study, and readers should calibrate their expectations accordingly. The Viewpoint is long on aspiration and appropriately cautious about execution: the gap between identifying use cases in a workshop and delivering a functioning clinical trial analytics ecosystem is considerable. The four enablers—standardization, quality, interoperability, transparency—are well-chosen and widely recognized in health informatics, but they are also the same barriers that have resisted progress for decades. Framing them as "enablers" rather than "obstacles" is diplomatically sensible but should not obscure how difficult each is to achieve at scale across multiple national registries, regulatory bodies, and institutional stakeholders. The ACT EU trial map is a tangible deliverable, though a patient-facing search tool, however useful, is a modest first step toward the ecosystem described. The integration of registry data with real-world data—repeatedly mentioned as high-value—raises methodological challenges around linkage, data provenance, and confounding that are acknowledged but not deeply addressed here. Whether the ACT EU initiative can translate a well-conducted workshop into durable infrastructure change remains to be seen. Worth watching, but primarily a policy and infrastructure agenda piece at this stage.

Relevance: Registry and Real-World Data Methods

Source: https://pubmed.ncbi.nlm.nih.gov/42881013/

---

Ashley Jaksa

Summary: This editorial in Value in Health argues that the real-world evidence (RWE) field has reached a state of "guidance oversaturation," in which regulators, health technology assessment bodies, and professional societies have collectively produced so many overlapping documents that researchers spend disproportionate effort comparing frameworks rather than generating evidence. The author contends that core principles—study design, data quality, fit-for-purpose data selection, methodological rigor—are already substantially aligned across major bodies such as the FDA and EMA. Rather than issuing additional high-level guidance, the field should prioritize two things: global harmonization of existing standards and the development of a transparent, annotated repository of real-world case studies illustrating actual decision-making.

Why it matters: For researchers working with patient registries, claims databases, or EHR-derived data, guidance fragmentation is a genuine operational burden—one that consumes resources without improving evidence quality. The proposal for a precedent-based, annotated case repository is practically interesting: regulatory and HTA decisions frequently hinge on tacit criteria that are never fully articulated in formal guidance, and making that reasoning visible would reduce uncertainty for sponsors and researchers alike. If adopted, harmonization efforts could also reduce the risk of evidentiary fragmentation across jurisdictions, a problem with direct consequences for rare-disease research where datasets are already small and cross-national pooling is often essential.

Expert perspective: This is a well-reasoned editorial making a point that many in the field privately acknowledge but rarely state this directly: the volume of RWE guidance has become its own problem. The argument that core principles already converge across major regulators is important and underappreciated—it suggests that the marginal value of yet another guidance document is low, while the cost in researcher attention is real. The two proposed solutions are sensible, though neither is trivial to execute. Global harmonization of guidance requires sustained political will across agencies that have distinct mandates, legal frameworks, and institutional cultures; the editorial does not fully grapple with what that process would look like in practice. The annotated case repository idea is compelling in principle, but its value depends entirely on how transparent decision-makers are willing to be about their reasoning—an openness that has historically been limited. This editorial does not present new empirical data and should be read as advocacy rather than evidence, but the advocacy is grounded and the diagnosis is credible. Worth reading for anyone who has found themselves assembling a spreadsheet comparing FDA, EMA, NICE, and ICER guidance documents and wondering whether the exercise was worth the effort.

Relevance: Registry and Real-World Data Methods

Source: https://pubmed.ncbi.nlm.nih.gov/42562111/

---

Seyyedeh Fatemeh Mousavi Baigi, Seyyed Mohammad Tabatabaei, Abbas Sheikhtaheri, et al.

Summary: This PROSPERO-registered systematic review synthesized 119 studies examining how data quality (DQ) in health and disease registries is conceptualized, measured, and improved, with particular attention to AI and machine learning approaches. Completeness and accuracy dominated as assessed dimensions, while representativeness and coverage were largely neglected. Conventional rule-based and audit methods remain the workhorses of registry DQ management, and AI/ML applications—though growing—remain selective and constrained by structural and interoperability barriers. The authors conclude that registry DQ management is still predominantly retrospective and fragmented rather than proactive and lifecycle-integrated.

Why it matters: Registries are increasingly central to regulatory decision-making, post-market surveillance, and real-world evidence generation, making data quality not a housekeeping concern but a scientific and policy-critical issue. The finding that representativeness and coverage—arguably the dimensions most consequential for generalizability and bias—are underassessed is a meaningful gap with direct implications for how registry-derived evidence should be interpreted. For rare diseases, where registries may capture a substantial fraction of the known population, completeness and representativeness failures can silently distort epidemiological estimates and treatment-effectiveness analyses.

Expert perspective: This is a methodologically conscientious review—PRISMA 2020 adherence, broad multi-database search through late 2025, and Mixed Methods Appraisal Tool quality appraisal all suggest reasonable rigor. That said, systematic reviews of heterogeneous registry literature inherit the limitations of their constituent studies: variable DQ definitions, inconsistent reporting standards, and a publication landscape that skews toward positive or novel findings. The thematic synthesis approach is appropriate but inherently qualitative, and the 119-study corpus likely reflects substantial heterogeneity in registry type, disease domain, and healthcare context that resists clean aggregation.

The finding that AI/ML remains selectively applied is credible and unsurprising. Anomaly detection and record linkage are natural entry points for ML precisely because they map onto well-defined computational tasks; fuzzier quality dimensions like clinical plausibility or longitudinal consistency are harder to automate without robust reference standards—which, as the review notes, are often absent. The call for "lifecycle-integrated quality ecosystems" is directionally correct but operationally underspecified, which is a common limitation of synthesizing aspirational literature.

For registry professionals and informaticists, the most actionable takeaway is the persistent neglect of representativeness and coverage assessment—dimensions that require external data linkage and population denominators, not just internal audits. Advancing these requires investment in interoperability infrastructure and data governance, not just better algorithms. The AI enthusiasm in this space is real but should not obscure the more foundational work still needed in standardized data definitions and sustainable audit processes.

Relevance: Registry and Real-World Data Methods

Source: https://pubmed.ncbi.nlm.nih.gov/42813616/

---

J Marin-Corral, N Iglesias, S Menke, et al.

Summary: This article describes the Savana Next-Generation Registry (SNGR), a methodology for constructing oncology-focused real-world data registries by extracting and structuring clinically relevant information from unstructured electronic health record (EHR) text using a multilingual natural language processing (NLP) engine called EHRead®. The system incorporates medical expert curation, terminology standardization, and a quality assurance framework intended to support reproducibility and regulatory compliance. To date, the platform has supported more than 65 real-world use cases and contributed to over 30 peer-reviewed publications across multiple therapeutic areas.

Why it matters: A substantial proportion of clinically meaningful information in EHRs resides in free-text narratives—clinical notes, discharge summaries, pathology reports—that remain inaccessible to conventional structured-data queries. Scalable NLP-based extraction that converts this information into analysis-ready datasets could meaningfully expand the scope and depth of real-world evidence, particularly in settings where staging, treatment response, and disease progression are often documented narratively. Alignment with European regulatory frameworks including the European Health Data Space and GDPR is operationally relevant as regulatory bodies increasingly consider RWE in decision-making.

Expert perspective: This paper is best characterized as a methods and infrastructure description rather than a primary research study, and it should be read accordingly. The abstract provides no head-to-head validation data—no systematic comparison of NLP-extracted variables against manual chart review or a reference standard across a defined sample. The claim of "methodologically robust infrastructure" therefore rests largely on the authors' own characterization and the volume of downstream use cases, neither of which constitutes independent validation. Thirty peer-reviewed publications are cited as evidence of the platform's utility, but publication count is a weak surrogate for data quality; it reflects adoption more than accuracy.

Key questions go unanswered in the abstract: What are the precision, recall, and F1 performance metrics of EHRead® across clinically critical variables? How does extraction performance vary across languages, institutions, and EHR systems? What proportion of records have sufficient free-text richness to yield complete, analysis-ready datasets, and how is missingness handled? The multilayer quality assurance framework is mentioned but not described in evaluable detail.

That said, the underlying problem the platform addresses is genuine and important. Structured EHR fields alone are demonstrably insufficient for complex RWE generation, and NLP-based enrichment is a legitimate and increasingly mature approach. The regulatory alignment work—particularly with the European Health Data Space—represents real operational value for multicenter and cross-border studies. For small patient populations where extracting maximum information from existing clinical documentation is essential, analogous infrastructure could prove highly relevant. Readers should treat this as a credible description of a functional platform with meaningful real-world deployment, while recognizing that independent, prospective validation of extraction accuracy across diverse clinical settings remains the critical unmet evidentiary standard.

Relevance: Registry and Real-World Data Methods

Source: https://pubmed.ncbi.nlm.nih.gov/42830900/

---

V Zadnik, A Duratović Konjević, M Jurtela, et al.

Summary: A cross-sectional survey conducted in early 2026 under the EU Joint Action CancerWatch mapped 175 population-based cancer registries (PBCRs) across 45 European countries, achieving a 91.1% response rate. The survey—the first of its kind at this scale—assessed coverage, data timeliness, digital infrastructure, and readiness to generate real-world data. Key findings include incomplete population coverage in some regions, only 69% of countries providing incidence data within two years, substantial variability in digital maturity, and roughly one-third of registries reporting limited or no awareness of European Health Data Space (EHDS) requirements.

Why it matters: Population-based registries are foundational infrastructure for epidemiological surveillance, health policy, and increasingly for RWD generation to support regulatory and clinical decision-making. Identifying where European registries fall short in timeliness, interoperability, and EHDS alignment is a necessary precondition for coordinated improvement. The survey's scope—over 700 items across 192 invited registries—provides an unusually granular baseline that could meaningfully inform EU-level investment and harmonization efforts. For rare diseases more broadly, where cross-national data pooling is essential to achieve adequate sample sizes, these gaps are particularly consequential.

Expert perspective: The study's principal strength is its exceptional response rate (91.1%) and breadth, which lend genuine credibility to the landscape portrait it paints. Cross-sectional self-reported surveys, however, are inherently limited: registry staff self-assessed their own digital maturity and EHDS awareness, introducing social-desirability bias and variable interpretation of survey items. The 700-item questionnaire also raises questions about respondent fatigue and data consistency across national contexts with differing definitions of "automated infrastructure" or "data linkage." That said, the directional findings—fragmented data exchange, lagging timeliness, uneven digital capacity—are plausible and consistent with what observers of European health data infrastructure have long suspected.

The 31% of registries reporting no or limited EHDS awareness is striking and arguably the most actionable finding, given that EHDS implementation timelines are not waiting for registries to catch up. The authors appropriately call for standardized, publicly accessible registry inventories and coordinated European action rather than overstating causal conclusions. This is honest and useful work: not a trial, not RWE in itself, but the kind of systematic baseline assessment without which intelligent infrastructure investment is impossible. The findings have direct relevance beyond the oncology context—rare disease registries face analogous heterogeneity in coverage and interoperability across European member states.

Relevance: Registry and Real-World Data Methods

Source: https://pubmed.ncbi.nlm.nih.gov/42830857/

---

Taryn Bessen, Stephen McDonald

Summary: This commentary from Bessen and McDonald argues that clinical quality registries (CQRs)—which systematically collect safety and quality data and generate risk-adjusted, benchmarked reports—frequently fail to drive improvement beyond the clinical unit or specialty level. The authors identify organisational infrastructure elements they consider essential for translating CQR data into health-system and jurisdictional quality improvement. The piece is perspective or commentary rather than an original empirical study.

Why it matters: The observation that registry-generated insights remain siloed within clinical teams is a well-recognised but underaddressed problem in healthcare quality improvement. If CQR data cannot inform governance decisions at the health-service or system level, the substantial investment in registry infrastructure yields only a fraction of its potential value. For rare diseases where registries serve as the primary source of real-world evidence and quality benchmarking, the same structural barriers apply, and the consequences for a small patient population can be disproportionately large.

Expert perspective: This is an opinion and framework piece, not an empirical study, so its claims cannot be evaluated by the usual criteria of sample size, confounding, or statistical precision. The core argument—that registry data need organisational embedding to drive improvement—is plausible, well-aligned with the broader quality-improvement literature, and reflects genuine operational experience. However, the article does not present comparative evidence that health services with the described infrastructure actually achieve better outcomes than those without it, which limits the strength of any causal claim.

The tension the authors identify is real: registries are often designed, funded, and governed within clinical specialty silos, while accountability for system-wide quality sits in executive and jurisdictional structures that rarely receive registry outputs in usable form. Bridging that gap requires not just technical data infrastructure but also governance mandates, leadership engagement, and agreement on which registry-derived indicators should trigger organisational action. None of these are trivial.

From a registry-methods standpoint, the piece implicitly raises important questions about data stewardship, reporting latency, and the usability of risk-adjusted outputs for non-clinical audiences. Benchmarking is only actionable if the recipients understand what the numbers mean and have authority to respond. For registries serving rare-disease populations, the added complication is that small denominators make risk adjustment statistically unstable at the unit level, which can frustrate exactly the kind of benchmarking the authors champion. Overall, this is a useful, practically oriented contribution that articulates a known gap and proposes an organisational solution. It would be strengthened considerably by empirical evidence—even case studies with outcome data—demonstrating that the recommended infrastructure elements actually improve registry uptake and downstream quality metrics. As it stands, it is well-reasoned advocacy rather than proven guidance.

Relevance: Registry and Real-World Data Methods

Source: https://pubmed.ncbi.nlm.nih.gov/42888857/

---